Trial · NCT05998395
JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease
NCT05998395, Phase 1, Phase 2, Completed, National Heart, Lung, and Blood Institute (NHLBI); results first posted 2026-02-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease. Trials, record NCT05998395. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05998395
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease
- NCT number
- NCT05998395
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Conditions
- Kohlmeier Degos Disease With Neurologic Involvement, Kohlmeier-Degos Disease
- Interventions
- Ruxolitinib
- First posted
- 2023-08-21
- Last updated
- 2026-02-03
- Results first posted
- 2026-02-03
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib | Baseline, up to 13 weeks | The primary endpoint is stability or regression of existing enhancing lesions or no development of new enhancing lesions in the brain and spine observed in MRI evaluation after 13 weeks and up to 73 weeks of ruloxitinib (10 mg BID) compared to pre-treatment MRI images. |
| Primary | Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib | 13 weeks up to 72 weeks | The primary endpoint is stability or regression of existing enhancing lesions or no development of new enhancing lesions in the brain and spine observed in MRI evaluation after 13 weeks and up to 73 weeks of ruloxitinib (10 mg BID) compared to pre-treatment MRI images. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib | Baseline, up to 13 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib | 13 weeks up to 72 weeks | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | Stabilization of Lesions | 1 | Participants | |
| Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | Regression of Lesions | 0 | Participants | |
| Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | New Lesions | 0 | Participants | |
| Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | Stabilization of Lesions | 0 | Participants | |
| Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | Regression of Lesions | 0 | Participants | |
| Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | New Lesions | 1 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | 1 | |
| Overall Study | COMPLETED | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | 0 | |
| Overall Study | NOT COMPLETED | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | 1 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Depression | Psychiatric disorders | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | 1 | 1 | 1 |
| other | Abnormal MRI | General disorders | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | 1 | 1 | 1 |
| serious | Worsening Sacral wound abscess | Skin and subcutaneous tissue disorders | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | 1 | 1 | 1 |
| serious | Anemia | Blood and lymphatic system disorders | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | 1 | 1 | 1 |
| serious | Bacteremia | Infections and infestations | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | 1 | 1 | 1 |
| serious | Sepsis | Infections and infestations | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | 1 | 1 | 4 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | 0 | 1 |
| Total, other adverse events | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | 1 | 1 |
| Total, serious adverse events | Ruxolitinib in Participants With CNS Kohlmeier-Degos Disease | 1 | 1 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42532045 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05998395
GET https://conductscience.org/api/trials/v1/NCT05998395/registered